The NDA submission in the next two weeks is the primary near-term catalyst. Monitor for FDA acceptance and any update on the NPV review timeline. The cash runway into 2028 removes near-term financing risk.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $8.59entry
- T+1 · 13d ago +0.12%α −1.54% · $8.60
- T+5 · 7d ago +7.68%α +8.27% · $9.25
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Compass Pathways reported Q3 2026 results with a GAAP net loss of $9.8M ($0.07 basic / $0.31 diluted per share), compared to a $137.7M loss in Q3 2025. The improved bottom line was driven by a $40.8M non-cash gain on warrant liabilities. The key catalyst is the imminent completion of the NDA submission for COMP360 in TRD, expected within two weeks, with potential for accelerated FDA review and commercial launch in H1 2027. Cash stood at $444M, sufficient into 2028.
Key Financial Metrics
Key Facts
- Final NDA submission for COMP360 in TRD will be filed in the next two weeks, with rolling review underway.
- National Priority Voucher could shorten FDA review to 1-2 months; White House Executive Order supports rapid DEA rescheduling.
- Commercial launch on track for H1 2027, subject to FDA approval.
- Cash and cash equivalents of $444M as of September 30, 2026, sufficient into 2028.
- Net loss of $9.8M in Q3 2026 vs $137.7M in Q3 2025, primarily due to a $40.8M non-cash gain on warrant liabilities.
- Operating loss of $56.4M in Q3 2026 vs $40.5M in Q3 2025, reflecting increased SG&A for commercial preparedness.
- 52-week open label data from COMP005 showed added benefit from an additional COMP360 25 mg dose extending durability to one year.
- Late-stage PTSD trial ongoing; collaboration with VA for TRD trial in veterans.
Financial Impact
Q3 2026 net loss $9.8M, operating loss $56.4M, cash $444M. No revenue.
Risk Factors
- FDA approval is not guaranteed; COMP360 is an investigational drug with no guarantee of regulatory success.
- DEA rescheduling is required before commercialization; timing is uncertain despite Executive Order support.
- Commercial launch depends on FDA approval and DEA action; delays could push launch beyond H1 2027.
- Operating losses are increasing as the company scales commercial infrastructure ahead of potential approval.
- Warrant liabilities create significant non-cash volatility in reported net income/loss.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001816590-26-000078 |
| Document: cmps-20261103.htm | 0001816590-26-000078 |
| Document: 0001816590-26-000078-index-headers.html | 0001816590-26-000078 |
| Document: 0001816590-26-000078-index.html | 0001816590-26-000078 |
| Document: 0001816590-26-000078.txt | 0001816590-26-000078 |
| 8-K Data (Synthetic) | 0001816590-26-000078 |
Track record
6 reports on CMPS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 3, 202613d ago 8-K Bullish 6/10 Viewing Entry $8.59 to $9.25 Now $8.27 −3.73% ▲ +7.68% +8.27% vs SPY
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $12.28 to $8.60 Now $8.27 −32.65% ▼ −29.97% −29.26% vs SPY
- Aug 10, 202614w ago 144 Neutral 3/10 Entry $13.18 to $13.72 Now $8.27 −37.25% ▲ +4.10% +4.14% vs SPY
- Aug 5, 202614w ago 8-K Neutral 5/10 Entry $13.58 to $14.22 Now $8.27 −39.10% ▲ +4.71% +4.36% vs SPY
- Jul 7, 202618w ago 8-K Neutral 3/10 Entry $12.99 to $13.39 Now $8.27 −36.34% ▲ +3.08% +2.53% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bullish 5/10 Entry $11.41 to $11.94 Now $8.27 −27.52% ▲ +4.64% +4.21% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers